Revisiting the rosiglitazone story--lessons learned.
Rosen
Clifford J
CJ
Maine Medical Center Research Institute, Scarborough.
D026683:Advisory Committees; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D017202:Myocardial Ischemia / Q000139:chemically induced*; D016017:Odds Ratio; D047495:PPAR gamma / Q000378:metabolism; D000077205:Pioglitazone; D057051:Product Recalls and Withdrawals; D012107:Research Design; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone